CTIS2022-500727-68-01
Recruiting
Phase 1
Perineural injections of incobotulinumtoxin-A for diabetic neuropathic pain of the lower extremities: A double-blind, randomized, placebo-controlled study (PINBOT)
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Diabetic neuropathic pain
- Sponsor
- Rigshospitalet
- Enrollment
- 80
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •18 years of age or older, Diagnosed with diabetes mellitus, type I or II, Diagnosed with diabetic neuropathic pain that is a) by the participant as their dominant overall dominant pain b) rated at least 4 out of 10 of the NRS pain scale in both legs on average over the past 7 days c) fulfils the IASP criteria for Definite chronic neuropathic pain d) has been verified using nerveconduction studies e) present in both legs, below the knee f) has been present for at least 6 months, In a stable analgesic treatment regime for at least 1 month prior to inclusion and for the duration of the study, Not been treated with topical agents such as capsaicin or lidocaine products in the affected areas for at least 3 months prior to inclusion, Using an approved, safe contraceptive (for premenopausal women), Speak, read, and understand Danish
Exclusion Criteria
- •A known allergy or hypersensitivity to botulinumtoxin, Using or receiving treatment with cannabis products of any kind, Pregnant or planning pregnancy during the study period, A score of more than 25 on the Charlson Comorbidity Index, Treated with botulinumtoxin in the last 6 months, Diagnosed with myasthenia, Eaton\-Lambert syndrome, or amyotrophic lateral sclerosis, A known malignant condition, An ongoing infection in the area of injection (right above the knee joint), Expect to change their pain medication during the study period, Diagnosed with a competing cause of central or peripheral neuropathic pain, or other painful chronic conditions of the lower extremities, such as spinal stenosis, claudicatio, previous traume or nerve injury or cancer related pain., A psychiatric condition that affects their completion of the study, as assessed by the investigator., Active abusers of alcohol or illegal substances
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
Subepithelial injection of onabotulinumtoxin A for overactive bladderRefractory overactive bladderJPRN-UMIN000040147Hokusuikai kinen Hospital Department of Urology40
Not Yet Recruiting
Phase 2
Injection Botulinum Toxin in post-surgery wound healingHealth Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynxCTRI/2024/03/064416Intraumural Grant
Active, Not Recruiting
N/A
Intraprostatic injection of Botulinumtoxin type A in patients with chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) - CP(BTX)PSEUCTR2007-001602-24-DEDepartment of Urology and Pediatric Urology - Justus-Liebig-University Giessen
Completed
N/A
Subepithelial injection of botulinum toxin A for non-neurogecic overactive bladderon-neurogenic overactive bladderJPRN-UMIN000001422ational Center for Geriatrics & Gerontology45
Completed
N/A
Subepithelial injection of botulinum toxin A for neurogecic detrusor overactivity (NDO) due to spinal cord injuryeurogenic detrusor overactivityJPRN-UMIN000001421ational Center for Geriatrics & Gerontology26